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Abstract 
Objective: Combined hormonal contraceptives (CHC) exhibit differing risks for cardiovascular and 
thrombotic events (VTE). A European referral process confirmed higher VTE risks for 3rd generation 
gestagens and drospirenone. CHC are now grouped in risk classes (RC) I, II and III, with RC III having 
a higher risk than RC I and X (risk not yet known). Marketing authorisation holders were obliged to 
implement pharmacovigilance measures and risk minimization measures including changes of 
prescribing information. The study assessed whether these activities induced changes in prescription 
patterns. Methods: German prescription data for 1.1 million women below 20 were used to analyse the 
effects of interventions and potential influence factors using logistic regression. Descriptive statistics 
were calculated for prescriptions for 3.3 million women from January 2011 to March 2016.  Results: 
Shares of RC I and RC X recipients rose substantially over the observation period, while RC III 
recipient share showed a steady decrease. The referral induced a slightly faster decrease in RC III 
and increase in RC X. The implementation of pharmacovigilance measures manifested no additional 
effect. Conclusion: The decrease in RC III share already observed before the referral process can be 
explained with pre-existing discussions around CHC. The effect attributable to the referral was 
statistically significant, though very small. While evidence for a connection between interventions and 
prescription change is only indirect, the study shows that routine data are suitable for impact analyses, 
and monitoring prescribing patterns can be recommended as feedback after regulatory or political 
interventions. This is being followed up. 
 
1. Introduction 
 
The risks of “the pill“ for contraception have frequently been reported internationally both in 
professional and in public media. An example of this was a brochure by a German health care fund1 in 
late 2015, which was widely discussed in the media. The focus on the brochure was the choice of 
contraception taking into account the spectrum of adverse effects, and in particular on 
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thromboembolism and myocardial infarctions. Already one year before, the manufacturers of 
combined hormonal contraceptives (CHC) had been obliged to include warnings regarding the 
increased risk of thromboembolism for what were, at that time, called 3rd and 4th generation 
gestagens, into their package inserts. This was a consequence of a European risk evaluation process 
(so-called referral process), which the European Medicines Agency (EMA) had initiated at the request 
of the French marketing authority2. The review confirmed a higher risk for the gestagens desogestrel 
and gestodene and also for drospirenone. For chlormadinone, dienogest and nomegestrol, no verdict 
could be reached based on available evidence3-6. It was anticipated that this process, and the 
implementation in the form of warnings, should lead to decreased prescribing of these CHCs. In the 
meantime, gestagens have been classified in risk classes instead of (historically motivated) 
generations. The CHC subject to the referral can be found in risk class (RC) I (norgestimate), III 
(desogestrel, gestoden, drospirenone), and X (nomegestrol, chlormadinone, dienogest). Risk class III 
shows a higher risk for venous thromboembolism (VTE) than class I7,8. For risk class X, no final 
assessment of VTE risk has been made. Risk assessment must take into account that these CHCs 
are typically taken for many years by women. Various epidemiological studies have shown that 60% of 
young women use oral contraception already at the age of 17, and by aged 19 this rises to 80%1,9. 
 
CHC prescribing patterns have been the subject of various studies, both nationally and internationally9-
13, including in the context of guidelines for the choice of hormone14,15. Developments though differ 
between countries. To the best of our knowledge, in Germany the impact of the referral process has 
not yet been studied. This study aims therefore to analyse whether the referral process, and the 
subsequent obligation for implementation of the pharmacovigilance measures, led to a change in CHC 
prescribing patterns. This is important not only to update current prescribing practices for CHCs in the 
most populous European country, but also emphasise whether additional pertinent interventions are 
needed to improve the prescribing of CHCs in Germany and wider. 
 
2. Material and methods 
 
2.1 Data and study population: 
Two data sources were employed. In order to be able to make conclusions for all CHC recipients 
independent of the specific health care fund women are covered by16, nation-wide prescription data of 
the German Statutory Health Insurance Rapid Drugs Information (GAmSi) were analysed. These are 
routinely collected as stipulated by law (article 84 section 5 of Social Code Book vol. V). These data, 
which are gathered through the pharmacy computing centres, are completely anonymous, i.e. they 
contain no reference to individuals. For approximately 3.3 million female insurees aged between 10 
and under 20, analyses can be broken down by substance, patients’ age, region (of doctors’ offices) 
and physician specialty. Results are presented per 1000 insured women in the age group. As an 
additional data set, we used nation-wide data (so-called Actrapid! data) of the largest German health 
care fund group, AOK, which includes an anonymous person identifier. CHC prescription data for 1.1 
million women (2nd quarter 2015) insured by AOK and aged between 10 and under 20 were used in 
order to assess the prevalence and incidence of treatment. Data included IDs for prescribing 
physicians, from which information on, e.g., physician specialty and region can be derived. Since both 
data sources consist of fully anonymised health claims data without any reference to individuals, no 
ethics approval was needed. 
 
The age group “10 to under 20 years“ was chosen to match previous German publications and 
information. The specific reason for this is that within the German statutory health insurance system, 
oral contraceptives are only reimbursed, with few exceptions, up to the 20th birthday. Due to this, there 
are no reliable health insurance routine data for other age groups. We also know from previous 
research that by the age of 19, 80%1,9 of young women use oral contraceptives. Since girls under the 
age of 15 contribute only very little to overall CHC use, we also include a description concentrating on 
the more relevant subgroup, i.e. 15 years to under 20 years.  
 
2.2 Hormonal substances in this study and their classification: 
The CHC studied are listed in Table 1, which also states their risk class and generation. 
 
Insert Table 1 here 
 
CHC treatment prevalence is calculated as the percentage of female insurees with at least one CHC 
prescription in the period at issue. A prescription is assumed to be incident if and only if there was no 
CHC prescription within the 365 days prior to the first prescription within the period at issue. Incidence 
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is calculated as the number of female insurees with a first prescription of a CHC, divided by 1000 
person years of the (sub)group studied. 
 
2.3 Design and reporting period 
The issues are analysed both descriptively and using time series analysis for the following four 
phases: 
 1st Jan 2011 to 31st Dec 2012: pre-intervention phase 
 1st Jan 2013 to 31st Jan 2014: referral phase 
 1st Feb .2014 to 31st Dec 2014: implementation of EMA conditions 
 1st Jan 2015 to 31st Mar 2016: post-intervention phaseϯ1 
 
2.4 Statistics  
Statistical analysis was performed using R 3.3.2. Development of the consumption of substance 
groups is shown descriptively as their respective shares on all CHC prescriptions and also as 
treatment prevalence. Regarding the time series analysis, for each risk class and each month in the 
study period, we calculated the number of women in the base population who had received a drug 
from the risk class at issue within that month. This number was then divided by the total number of 
women within the base population who had received any CHC within that month. We chose to work 
with these shares instead of absolute values since the absolute prescription volume varies 
substantially between months. This variation is partly due to the German system of defining cases of 
treatment on a quarterly base, which imposes a strong three-month rhythm on all ambulatory 
treatment volumes, and in particular on prescribing. In addition shifting public holidays, and especially 
school holidays, can lead to stockpiling of prescriptions. Both these factors are independent of 
prevalence and must therefore be eliminated from the analysis.  
 
The time series were analysed using an extension of ARIMA (autoregressive integrated moving 
averages) models17 such that the effects of interventions at known points in time could be assessed. 
ARIMA is often used for time series analyses, when the observations for the various time points are 
not independent of each other (auto-correlation of measurements).   
 
As points of intervention we chose (a) the start of the referral process (January 2013) and (b) the start 
of the implementation of EMA conditions through prescribing information from the marketing 
authorisation holders and through Dear Doctor letters (start of February 2014). Fitting the models 
involved first a visual check of the residuals of the auto-correlation and the partial auto-correlation 
functions (ACF and PACF, respectively).  For checking that the residuals were free of auto-correlation, 
the Ljung-Box Q-test was used. Existence of a unit root was tested with the Augmented Dickey-Fuller 
test. 
 
After an appropriate model of the time series process had been developed, the influence of 
exogeneous interventions could be assessed. For each of the two interventions a binary dummy 
variable was introduced, which had the value 0 for the months before the respective intervention and 1 
for every month starting with the month of intervention. Subsequently, the model was augmented with 
two interventional components as functions of the dummy variables. If an interventional component 
increases the explanatory power of the model by a statistically significant amount, this justifies the 
conclusion that the respective intervention had a statistically significant influence on the time series17.  
 
Both interventions were modelled as gradual onset and permanent effect. The extended model 
therefore has one additional pair of parameters (ω and δ, cf. below) per intervention. Further 
explanations can be found in Table 2. 
 
Insert Table 2 
 
Regarding the logistic regression, for assessing the factors influencing the first observed instance of a 
prescription of a certain CHC risk class only those insurees are included who received a CHC from 
risk classes I or III in the post-intervention phase (January 2015 until March 2016) and no drug of the 
respective risk class in the 365 days prior to that prescription. For insurees who received both a CHC 
                                                          
Ϯ Time series analyses of prevalences was limited up until Oct 2015. Annual prevalences are shown 
only up to 2015, inclusively.  
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of risk class I and risk class III drug in the post-intervention phase, only the first such prescription in 
time is included.  
 
Further factors included were patient ages, previous CHC status (naïve vs. use of drugs from some 
other risk class) and physician-related factors age (of physician), gender, region (by Doctors’ Regional 
Association – Kassenärztliche Vereinigung, KV) and specialty. The significance of the contribution 
which the various factors added to the logistic regression model was tested using the Wald test. 95% 
confidence intervals (CI) were calculated according to the formula: 
 
 ˆ ˆ1 /2 1 /2ˆ ˆ( ) , ( )j jj je SE z e SE z        , where ˆ j  is the estimated parameter, ˆ( )jSE   is the 
standard error of the estimate and z1-α/2 is the quantile of normal distribution (in our case α = 0.05). 
 
 
Since the study used only anonymised claims data of health insurance funds (secondary data use), no 
ethics committee approval was necessary. This is similar to other published studies19. 
 
3. Results 
 
3.1 Development of CHC prescriptions 
GAmSi data (data source A) show a steady increase in defined daily doses (DDD)18 in all four phases 
for CHC in RC I and RC X (in total +12% and +37%, respectively) (Table 3). The DDD amount of RC II 
contraceptive medicines (vaginal preparations) is roughly constant on a low level. A substantial 
decrease (– 53%) occurs for RC III. This reflects also in the decreasing share of these CHCs as part 
of total CHC consumption. CHC consumption was almost constant over time at +4%.  
 
Insert Table 3 
 
The decrease of prescriptions of RC III drugs is comparable for both gynaecologists and general 
practitioners (GPs). However, GPs exhibit a higher increase of RC X drugs compared to 
gynaecologists (+38% vs. +30%, respectively). The importance of GPs as CHC prescribers decreased 
between 2010 (17.2% of total CHC DDDs) and 2015 (12.4%). The main prescribers, as expected in 
Germany, are gynaecologists. 
 
3.2 Development of prevalence and incidence among AOK insurees 
Data source B shows a decrease in the number of young women with at least one CHC prescription 
between 2011 and 2015 (0.356 million and 0.322 million respectively) due to a decrease in the 
number of women in this age bracket (the share of CHC recipients stayed constant at 30%) (Table 
4a). Treatment prevalence of RC I was also slightly decreasing in absolute figures, but the share of 
RC I recipients on all CHC recipients grew from 35% in 2011 to 38% in 2015. The highest increase is 
observed for RC X. RC III shows, by contrast, a steady decrease. RC X has the highest incidence 
(Table 4b) in the various phases, the highest increase though happens for RC I. While RC I incidence 
share on all CHC was 38% before the referral, in the post-intervention phase it was nearly 44%. The 
number of new RC III recipients decreased by 21% during this period. Since CHC use below the age 
of 15 is very rare, the main group of users within the target population (i.e., starting at 15 and below 
20) is documented separately in Table 4 b.   
 
Insert Tables 4a and 4b 
 
3.3 Development of the relative importance of the various risk classes 
The development over time of the share of recipients of the various risk classes is displayed in 
Figure 1. The vertical lines mark the points in time of the interventions (start of referral and of 
implementation, respectively) used in modelling. 
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Figure 1: Recipients of CHC: Share of all CHC recipients in the study population 
 
NB: The two vertical lines mark the start of the European risk assessment process (left line) and the point in time 
of the implementation (right line). Note that the y axes are scaled differently in order to show the values more 
clearly even though levels are different. 
 
The analysis of the temporal trend for RC III shows a statistically significant decrease for the first 
month of the referral phase (change in the share of prevalent cases by ω=-0.0035, i.e. a decrease by 
0.35 percentage points, p<0.001). This indicates that the pre-existing decrease of RC III treatment 
prevalence was slightly enhanced by the referral process (interpreted here as a factor of influence). 
However, the second intervention (implementation of EMA conditions) showed no statistically 
significant effect. In other words, the decrease observed during the referral phase was not enhanced 
any further. For RC X drugs there is also a statistically significant effect of the referral phase on the 
development of prescription; however, this was in the opposite direction, i.e. after the start of the 
referral, prescriptions increased more strongly than in the months before (+0.46 percentage points, 
p=0,009). The estimate for the asymptotic total effect of the start of the referral process is roughly 1 
percentage point. Like RC III, RC X showed no additional effect of the start of implementation (Table 
5). 
  
Insert Table 5  
 
3.4 Factors influencing incidence 
For insurees who received a RC I or III CHC for the first time during the post-intervention phase, 
factors influencing the prescription were investigated (Table 6). The odds of receiving a RC III CHC 
rather than a RC I CHC is almost three times as high when the insuree had received a CHC of a 
different class before. It doubles whenever a GP rather than a gynaecologist is the prescriber. There 
are also marked regional differences. In the federal state of Saarland, the odds compared to Baden-
Württemberg are 1.3, while for Bremen it is only 0.77 (Table 6). The odds for receiving a RC III drug is 
roughly 25% lower whenever the prescribing physician is female. 
 
Insert Table 6 
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4. Discussion  
 
4.1 Comparison with other studies of CHC prescribing patterns  
For the pre-referral period, the results from the present analysis are similar to the study by Ziller et 
al.20, which analysed contraceptive prescriptions to women aged 12 to 18 for the years 2007 and 2011 
based on prescription data from 167 gynaecological offices. The authors described an increase in 
treatment prevalence for levonorgestrel (RC I) and chlormadinone (RC X) as well as a decrease for 
drospirenone (RC III) and desogestrel (RC III). They stated that gynaecologists had changed their 
prescribing habits according to then available evidence of risk for VTE. At that time, however, 3rd and 
4th generation CHC (as they were called at the time) had already been critically assessed with respect 
to their risk for thromboembolism, and further data on drug safety had been called for. An analysis of 
claims data by German health care fund Techniker Krankenkasse1 for the years 2011 to 2013 also 
supports our finding that many young women received contraceptives of high or unclear risk. Changes 
from rather low risk drugs to those of higher or unclear risk were described. A similar pattern is 
reported by Bezemer et al. for the Netherlands, the UK, and Italy, in the period from 2009 to 2010 
looking at women aged 16 to 49 years21. However, the authors also point out country-specific 
differences in the choice of CHC. In the Netherlands, predominantly 2nd generation CHCs were used 
at the time (79%), whereas in the other two countries 3rd generation CHCs were more common (UK: 
44%, Italy: 62%). Similarly, according to our data, the share of 3rd and 4th generation on all CHC was 
around 67% during the period from 2011 to 2012.  
 
We found regional differences in RC III use in line with regional data reported for CHC use in general 
by Boeschen et al.1 Regional variations in health care use and prescribing are often reported,22,23 but 
valid explanations are still an issue for research. As possible influencing factors we can therefore only 
assume, amongst others, differences in risk communication and policies. 
 
4.2 Intervention analyses performed in other countries 
An impact analysis of administrative measures was also performed by Briggs et al.24. The authors 
studied whether the guidelines from 2006 for prescribing CHCs depended on an individual risk 
assessment for each woman were actually employed. The share of women who were advised not to 
use a CHC due to their risk profile had decreased significantly since the publication of the guidelines, 
but the authors nevertheless describe it as too high given that better alternatives are available for 
prescribing. Successful intervention of the Danish Institute of Rational Pharmacotherapy in favour of 
prescribing 2nd generation CHC (levonorgestrel) is reported by Løkkegard and Nielsen12. Between 
2010 and 2013, the number of recipients of 3rd and 4th generation CHC substantially decreased (–65% 
and –77%, respectively for the age group 14 to 19 years). Lemaitre et al.10 report a similar 
development for France in 2012 und 2013, after a series of measures for influencing prescribing 
practice had been taken.  
 
4.3 Limitations and strengths 
As with all studies based on claims data, only prescription and redemption in the pharmacy can be 
observed but not actually taking the medicine. While the data sources allow extended periods of time 
to be observed and analysed, a limitation is that only indirect conclusions can be made since other 
possible factors of influence cannot be directly accounted for. The influence of any such factors is, 
however, minimised by the statistical design chosen, viz., comparison against secular trends, which is 
a standard method used for impact analysis25. 
 
We are also aware that the study only includes women up to their 20th birthday because, as 
mentioned, only for this group can complete prescription data from health care fund claims data can 
be accessed. We cannot prove that the results are transferable to other age groups; however, we 
believe there are strong hints to this effect. According to IMS data (2014)1 more than half of the most 
frequently used contraceptives belong to risk classes III or X.  
 
For modelling the time series, we used the period from January 2011 to October 2015. The period of 
observation was cut short by several months compared to initial plans because there seemed to be a 
substantial change of trends starting from the end of 2015, which stands in no plausible connection to 
the interventions studied here. Including the period at the very end would have had repercussions on 
the whole model and might have hidden the effect of the interventions studied here. Any causes for 
further changes were outside the scope of this study. 
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Among the strengths of the study are its use of two different data sources for controlling health care 
fund specific bias16, the size of the data, and the long period of observation. Of particular interest is the 
linkage of prescriptions to selected characteristics of both receivers and prescribers, which made it 
possible to study factors influencing the prescribing patterns. The study shows that routine data can 
be used to obtain evidence on the impact of regulatory measures.  
  
5. Conclusion 
 
To the best of our knowledge, we believe this is the first study to investigate changes of prescribing 
patterns in connection with the referral process in Germany and wider. It is evident that such changes 
have already taken place before the start of the referral. This comes as no surprise given that the 
safety of contraceptives had been widely discussed in professional circles. The risks of oral 
contraceptives have been assessed as early as 1996 and again in 2001. This sets the context for the 
development of prescriptions and the effects described here. Proving a separate effect of the 
implementation of the conditions imposed by EMA is complicated by the fact that the marketing 
authorisation holders changed the prescribing information only step by step; hence, any effect is more 
difficult to separate from simultaneously occurring secular changes in prescribing. In addition, the 
ongoing effect of the start of the referral process on the perception within professional circles may 
“mask” any effect the second, additive intervention may have had.  
 
It merits separate discussion whether the small, although statistically significant effects of the first 
intervention, have practical significance. But similarly, to observe no separate statistically significant 
effect of the second intervention should not lead to the conclusion that the conditions imposed by the 
marketing authorisation bodies were superfluous. In particular, in our opinion, they may have 
contributed to persisting the observed decreases. Not allowing to let the evidence slip from the mind of 
prescribers may prevent later increases. For reasons of principle, however, such effects are not 
amenable to proof by observing factual developments of prescription. 
 
There are only hypotheses on the causes for the developments observed. Amongst others, it is an 
open question whether the warnings provided in prescribing information documents and in package 
inserts were sufficient. E.g., arznei-telegramm, an independent drug information journal, criticised in 
2015 the phrasing used for prescribing information and suggested an unequivocal labelling of these 
CHC as “medicines of subordinate choice”26. Control of usage may also be achieved through rules for 
reimbursement and regulatory policies like in France.  
 
Ongoing medical education in this area addresses mostly gynaecologists in Germany; however, GPs 
are also implicated in these prescriptions. They are in need of guidance for these medicines and their 
associated risks. We have been able to show that the risk of receiving a CHC with unfavourable risk 
profile is substantially increased among GPs compared to gynaecologists. This suggests that the 
communication of risks to GPs can still be improved upon and not be left to pharmaceutical 
companies. Substantial regional differences might also be explained by different information and risk 
communication policies in the various regions. This also needs to be addressed to ensure appropriate 
contraception for young women in Germany and wider. These are projects for the future  
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Tables 
Table 1 Combined hormonal contraceptives 
Risk 
class 
Gene-
ration 
ATC 
code
†
  
Drug combination Fixed 
combination 
(F)/sequential 
preparation 
(S) 
Relative 
risk 
compared 
to levonor-
gestrel 
Estimate of 
incidence 
(per 1000 
women per 
year) 
I 1 G03AA05  norethisteron and ethinylestradiol F   
I 1 G03AB04  norethisteron and ethinylestradiol S   
I 2 G03AA07  levonorgestrel and ethinylestradiol F (reference) 5–7 
I 2 G03AB03  levonorgestrel and ethinylestradiol S (reference) 5–7 
I 3 G03AA11  norgestimat and ethinylestradiol F 1.0 5–7 
I 3 G03AB09  norgestimat and ethinylestradiol S 1.0 5–7 
II (vagi-
nal) 
G02BB01  vaginal ring with gestagens and 
estrogens 
n/a   
II (vagi-
nal) 
G03AA13  norelgestromin and ethinylestradiol F 1.0–2.0 6–12 
III 3 G03AA09  desogestrel and ethinylestradiol F 1.5–2.0 9–12 
III 3 G03AA10  gestoden and ethinylestradiol F 1.5–2.0 9–12 
III 3 G03AB05  desogestrel and ethinylestradiol S 1.5–2.0 9–12 
III 4 G03AA12  drospirenone and ethinylestradiol F 1.5–2.0 9–12 
X 4 G03AA14  nomegestrol and estradiol F Unknown 
X 4 G03AA15  chlormadinone and ethinylestradiol F Unknown 
X 4 G03AA16  dienogest and ethinylestradiol F Unknown 
X 4 G03AB07  chlormadinone and ethinylestradiol S Unknown 
X 4 G03AB08 dienogest and estradiol S Unknown 
† ATC: Anatomical therapeutic chemical classification18 
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Table 2: Explanation of the parameters shown in Table 5 
Parameter  Explanation 
O(AR)  Order of auto-correlation in the ARIMA model 
O(I)  Order of differences in the ARIMA model 
O(MA)  Order of the moving averages in the ARIMA model 
ARn Auto-correlation coefficient of order n 
MAn  Moving averages coefficient of order n 
ωn† Effect on level of the nth intervention 
δn‡ Effect on slope of the nth intervention 
AIC  Akaike Information Criterion of the model (Measure of model quality: the 
lower the value, the more informative the model) 
LBT  Test statistic (2) and 𝑝-value of the Ljung-Box Q-test for the model (aim 
to have p > 0,05) 
ADF  Test statistic and 𝑝-value of the Augmented Dickey-Fuller tests for the 
model (aim to have p < 0,05) 
† Parameter 𝜔 estimates the difference between the share of prevalent cases in the first month after the respective 
intervention as it was actually observed on the one hand, and as it would have then been expected to be without the 
intervention. This is the effect in the first month only. 
‡ Parameter 𝛿 describes how the monthly differences develop afterwards. For the second month after the intervention 
the effect of the first month is assumed to persist (“permanent effect”), but an additional effect is assumed (“gradual 
onset”). This additional effect is described by 𝛿 ⋅ 𝜔. The total effect for the second month compared to the expected 
value without any intervention is therefore  𝜔 + 𝛿 ⋅ 𝜔. Analogously, the total effect in the third month will be 𝜔 + 𝛿 ⋅
𝜔 + 𝛿2 ⋅ 𝜔 etc. If 𝛿 is non-negative and less than 1, the asymptotic total effect over time will be 𝜔/(1 − 𝛿). This value 
can thus be interpreted as an estimate for the long-term effect of the intervention. The speed with which this long-term 
effect is approximated is described by parameter 𝛿: The smaller the value of 𝛿, the faster the monthly effect figures will 
approach the final value. (In the extreme case of 𝛿 = 0 the maximum effect would be reached immediately after the 
intervention, whose effect would then be shock-like.) It should be noted that these considerations are valid only if 
parameter 𝜔 is significantly different from 0. Otherwise, one cannot assume to have shown an effect of the intervention. 
(The present study follows the widespread convention of a 5% level for significance.) The estimate for the asymptotic 
long-term effect is valid only if the value of 𝛿 is also significantly different from 0. Otherwise, one could not exclude with 
sufficient certainty that 𝛿 = 0. In this case, as noted above, the effect in the first month would already be the final value. 
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Table 3: Development of DDD
†
 per year per 1000 insured women in the age between 10 and under 
20, broken down by CHC
‡
 risk classes  
Risk class Pre-Intervention Referral Implementation Post-Intervention Ratio 
 
 A B C D D/A 
I 26,122.7 27,667.6 28,448.2 29,225.6 1.12 
II 1,991.2 2,029.4 2,002.5 1,932.2 0.97 
III 21,353.0 14,825.9 12,138.7 9,933.6 0.47 
X 32,334.7 40,235.2 43,736.1 44,144.2 1.37 
Total 81,801.5 84,758.2 86,325.5 85,235.5 1.04 
Share of III 
on Total (%) 
26.1 17.5 14.1 11.7 0.45 
All phases are normalised to a length of 12 months.  
† DDD: defined daily dose, ‡ CHC: combined hormonal contraceptives 
Table 4 a: Annual prevalence (in 1000 units) of risk classes for AOK-insured† women aged 
10 to under 20 years 
Risk 
class  
2011 2012 2013 2014 2015 
I  126.6 (35.4%) 124.2 (36.0%) 120.4 (35.7%) 119.8 (36.0%) 122.9 (38.1%) 
II  11.2 (3.1%) 10.8 (3.1%) 10.6 (3.1%) 10.1 (3.0%) 9.8 (3.0%) 
III  109.9 (30.7%) 83.4 (24.2%) 65.1 (19.3%) 52.1 (15.7%) 41.8 (13.0%) 
X  142.0 (39.7%) 155.8 (45.2%) 170.2 (50.5%) 176.0 (52.9%) 172.3 (53.4%) 
Total  357.7 (100.0%) 345.0 (100.0%) 337.3 (100.0%) 332.4 (100.0%) 322.4 (100.0%) 
†AOK: Local health care funds 
Table 4 b: Incidence per 1000 insuree years of CHC† recipients aged under 20, broken down 
by risk class 
Risk class  Pre-intervention  Referral  Implementation  Post intervention  Ratio 
  (A)   (B)   (C)   (D)   (D/A) 
All age groups (10 to under 20) 
I   58.2   67.8   84.7   118.3   2.03 
II   2.9   3.6   4.1   5.1   1.76 
III   27.3   24.4   24.1   21.7   0.80 
X   66.4   94.6   112.2   125.6   1.89 
Total   154.7   190.4   225.1   270.7   1.75 
      
Subgroup 15 to under 20 
I  83.5 83.2 93.1 120.6 1.45 
II  4.4 4.6 4.8 5.5 1.24 
III  41.1 30.8 27.7 23.4 0.57 
X  96.2 117.0 127.0 132.7 1.38 
Total  225.2 235.6 252.6 282.3 1.25 
† CHC: combined hormonal contraceptives 
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Table 5: Model parameters for the various risk classes 
Parameter Risk class I Risk class III Risk class X 
Value Std Err p-Value Value Std Err p-Value Value Std Err p-Value 
O(AR) 4   2   2   
O(I) 1   2   2   
O(MA) 0   2   1   
AR1 -0.6398 0.114 <0.001 -0.8791 0.113 <0.001 -0.5868 0.187 <0.001 
AR2 -0.0738 0.098 0.453 -0.7928 0.094 <0.001 -0.6313 0.112 <0.001 
AR3 0.7465 0.100 <0.001       
AR4 0.4909 0.114 <0.001       
MA1     -0.6980 0.192 <0.001 -0.5897 0.128 <0.001 
MA2     0.2854 0.195 0.143    
δ1  -0.0000 n/a n/a 0.3421 0.246 0.165 0.5201 0.255 0.041 
ω1  0.0002 n/a n/a -0.0035 0.001 0.001 0.0046 0.002 0.009 
δ2  0.0000 n/a n/a 0.4900 0.350 0.161 0.0055 n/a n/a 
ω2  -0.0006 n/a n/a -0.0018 0.001 0.179 0.0000 n/a n/a 
AIC -504.0069   -526.3275   -496.2445   
LBT 25.0452  0.200 15.1708  0.767 13.0957  0.905 
ADF -3.4982  0.050 -3.5291  0.047 -3.5694  0.044 
Legend: cf table 2 
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Table 6: Odds Ratio for incident recipients of risk class III compared to risk class I during the 
post-intervention phase 
 
Factor Value Odds Ratio (95% CI) p-value† 
Intercept   0.108  (0.088, 0.134) < 0.001 
Age  1.049  (1.037, 1.062) < 0.001 
Region Baden-Württemberg Reference   - 
 Bavaria 1.037  (0.973, 1.105)  0.266 
 Berlin 1.116  (0.965, 1.288)  0.135 
 Brandenburg 0.956  (0.808, 1.126)  0.593 
 Bremen 0.766  (0.617, 0.943)  0.014 
 Hamburg 0.859  (0.710, 1.034)  0.114 
 Hesse 0.925  (0.841, 1.017)  0.108 
 Mecklenburg-Vorpommern 1.090  (0.913, 1.295)  0.333 
 Lower Saxony 0.878  (0.816, 0.945) < 0.001 
 North-Rhine 1.007  (0.934, 1.085)  0.855 
 Rhineland-Palatinate 0.964  (0.868, 1.069)  0.487 
 Saarland 1.293  (1.030, 1.614)  0.024 
 Saxony 0.784  (0.710, 0.864) < 0.001 
 Saxony-Anhalt 0.801  (0.686, 0.933)  0.005 
 Schleswig-Holstein 0.965  (0.856, 1.086)  0.555 
 Thuringia 1.017  (0.902, 1.146)  0.780 
 Westphalia-Lippe 1.170  (1.084, 1.263) < 0.001 
 Unknown 0.788  (0.319, 1.756)  0.579 
Specialty Gynecologists Reference   - 
 General practitioners 1.973  (1.830, 2.126) < 0.001 
 Other 1.189  (0.899, 1.565)  0.220 
Physicians’ Gender Male Reference   - 
 Female 0.752  (0.720, 0.785) < 0.001 
 Unknown 1.020  (0.795, 1.302)  0.876 
Age of physician Under 45 Reference   - 
 45 to below 60 1.004  (0.949, 1.063)  0.881 
 60 and older 1.032  (0.965, 1.103)  0.363 
Patient’s CHC status Naïve Reference   - 
 Previously exposed 2.780  (2.663, 2.901) < 0.001 
†p-values obtained from Wald test.  
 
